In addition, combined therapy did not reduce tumor-infiltrating Treg cells but transformed them into an effector phenotype that expresses a Th1 signature and cooperates with CD8 T cells to kill CT-26 tumor cells through TCR-MHC engagement-dependent mechanisms. The gene discussed is HLA-C; the disease is neoplasm.